Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Diamedica Therapeutics Inc (NQ: DMAC ) 4.340 +0.050 (+1.17%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Diamedica Therapeutics Inc < Previous 1 2 3 4 5 Next > DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia October 09, 2024 From DiaMedica Therapeutics Inc. Via Business Wire This Fastenal Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday October 07, 2024 Via Benzinga DiaMedica Therapeutics Upcoming Conference Participation September 04, 2024 From DiaMedica Therapeutics Inc. Via Business Wire DMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q2 2024 August 07, 2024 DMAC stock results show that DiaMedica Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace Recap: DiaMedica Therapeutics Q4 Earnings March 19, 2024 Via Benzinga Earnings Outlook For DiaMedica Therapeutics November 10, 2023 Via Benzinga DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results August 07, 2024 From DiaMedica Therapeutics Inc. Via Business Wire DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024 August 01, 2024 From DiaMedica Therapeutics Inc. Via Business Wire DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia July 11, 2024 From DiaMedica Therapeutics Inc. Via Business Wire DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement July 01, 2024 From DiaMedica Therapeutics Inc. Via Business Wire DiaMedica Therapeutics Announces $11.8 Million Private Placement June 26, 2024 From DiaMedica Therapeutics Inc. Via Business Wire DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia June 26, 2024 From DiaMedica Therapeutics Inc. Via Business Wire DMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q1 2024 May 08, 2024 DMAC stock results show that DiaMedica Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results May 08, 2024 From DiaMedica Therapeutics Inc. Via Business Wire DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024 May 02, 2024 From DiaMedica Therapeutics Inc. Via Business Wire DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke April 17, 2024 From DiaMedica Therapeutics Inc. Via Business Wire DMAC Stock Earnings: DiaMedica Therapeutics Meets EPS for Q4 2023 March 19, 2024 DMAC stock results show that DiaMedica Therapeutics met analyst estimates for earnings per share the fourth quarter of 2023. Via InvestorPlace DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results March 19, 2024 From DiaMedica Therapeutics Inc. Via Business Wire DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference January 29, 2024 From DiaMedica Therapeutics Inc. Via Business Wire DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer January 22, 2024 From DiaMedica Therapeutics Inc. Via Business Wire DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results November 13, 2023 From DiaMedica Therapeutics Inc. Via Business Wire DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023 November 09, 2023 From DiaMedica Therapeutics Inc. Via Business Wire DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023 November 06, 2023 From DiaMedica Therapeutics Inc. Via Business Wire Earnings Scheduled For November 13, 2023 November 13, 2023 Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter. Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday October 25, 2023 Pre-market stock movers are a hot topic on Wednesday and we're offering all the details that investors need to know about this morning. Via InvestorPlace DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer September 12, 2023 From DiaMedica Therapeutics Inc. Via Business Wire DiaMedica Therapeutics to Participate at Lake Street’s 7th Annual Best Ideas Growth Conference September 06, 2023 From DiaMedica Therapeutics Inc. Via Business Wire DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results August 14, 2023 From DiaMedica Therapeutics Inc. Via Business Wire DiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023 August 08, 2023 From DiaMedica Therapeutics Inc. Via Business Wire DiaMedica Therapeutics to Attend the American Academy of Neurology Summer Conference July 18, 2023 From DiaMedica Therapeutics Inc. Via Business Wire < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.